Parkinson’s Treatment Report

www.ParkinsonsTreatmentReport.com

Phase 2

A Clinical Study of NLY01 in Patient’s With Early Parkinson’s Disease

https://clinicaltrials.gov/ct2/show/NCT04154072?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=10%2F23%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
A Clinical Study of NLY01 in Patient’s With Early Parkinson’s Disease

DESCRIPTION:
Condition:   Parkinson Disease
Interventions:   Drug: NLY01;   Drug: Vehicle
Sponsor:   Neuraly, Inc.
Not yet recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT04154072

FIRST POSTED:
Wed, 06 Nov 2019 12:00:00 EST

LAST UPDATE POSTED:
11/06/19 08:26AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT04154072?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=10%2F23%2F2019&lupd_d=14&sort=nwst

Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson’s Disease

https://clinicaltrials.gov/ct2/show/NCT03318523?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F15%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson’s Disease

DESCRIPTION:
Condition:   Parkinson’s Disease
Interventions:   Drug: Placebo;   Drug: BIIB054
Sponsor:   Biogen
Active, not recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT03318523

FIRST POSTED:
Tue, 24 Oct 2017 12:00:00 EDT

LAST UPDATE POSTED:
05/29/19 07:29AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03318523?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F15%2F2019&lupd_d=14&sort=nwst

Simvastatin as a Neuroprotective Treatment for Moderate Parkinson’s Disease

https://clinicaltrials.gov/ct2/show/NCT02787590?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F18%2F2020&lupd_d=14&sort=nwst

STUDY TITLE:
Simvastatin as a Neuroprotective Treatment for Moderate Parkinson’s Disease

DESCRIPTION:
Condition:   Parkinson Disease
Interventions:   Drug: Simvastatin;   Drug: Matched Placebo (for Simvastatin)
Sponsors:   University Hospital Plymouth NHS Trust;   University of Plymouth
Active, not recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT02787590

FIRST POSTED:
Wed, 01 Jun 2016 12:00:00 EDT

LAST UPDATE POSTED:
06/01/20 07:10AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT02787590?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F18%2F2020&lupd_d=14&sort=nwst

TSPO-PET for Neuroinflammation in Parkinson’s Disease

https://clinicaltrials.gov/ct2/show/NCT03457493?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=04%2F13%2F2020&lupd_d=14&sort=nwst

STUDY TITLE:
TSPO-PET for Neuroinflammation in Parkinson’s Disease

DESCRIPTION:
Condition:   Parkinson Disease
Intervention:   Drug: DPA-714-PET/MRI
Sponsor:   University of Alabama at Birmingham
Recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT03457493

FIRST POSTED:
Wed, 07 Mar 2018 12:00:00 EST

LAST UPDATE POSTED:
04/27/20 09:21AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03457493?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=04%2F13%2F2020&lupd_d=14&sort=nwst

Effect of Melatonin Administration on the PER1 and BMAL1 Clock Genes in Patients With Parkinson’s Disease

https://clinicaltrials.gov/ct2/show/NCT04287543?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=02%2F13%2F2020&lupd_d=14&sort=nwst

STUDY TITLE:
Melatonin on Clock Genes in Parkinson’s Disease

DESCRIPTION:
Condition:   Parkinson Disease
Interventions:   Drug: Melatonin;   Drug: Placebos
Sponsor:   Instituto Mexicano del Seguro Social
Enrolling by invitation

CLINICALTRIALS.GOV IDENTIFIER:
NCT04287543

FIRST POSTED:
Thu, 27 Feb 2020 12:00:00 EST

LAST UPDATE POSTED:
02/27/20 09:09AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT04287543?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=02%2F13%2F2020&lupd_d=14&sort=nwst

A Study to Evaluate NYX-458 in Subjects With Mild Cognitive Impairment Associated With Parkinson’s Disease

https://clinicaltrials.gov/ct2/show/NCT04148391?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=10%2F18%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
Evaluate NYX-458 in Subjects With MCI-PD

DESCRIPTION:
Conditions:   Parkinson’s Disease;   Mild Cognitive Impairment
Interventions:   Drug: Placebo Oral Capsule;   Drug: NYX-458
Sponsors:   Aptinyx;   CogState Ltd.;   Worldwide Clinical Trials
Not yet recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT04148391

FIRST POSTED:
Fri, 01 Nov 2019 12:00:00 EDT

LAST UPDATE POSTED:
11/01/19 07:39AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT04148391?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=10%2F18%2F2019&lupd_d=14&sort=nwst

Transplantation of Neural Stem Cell-Derived Neurons for Parkinson’s Disease

https://clinicaltrials.gov/ct2/show/NCT03309514?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=09%2F12%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
Transplantation of Neural Stem Cell-Derived Neurons for Parkinson’s Disease

DESCRIPTION:
Condition:   Parkinson’s Disease
Intervention:   Biological: Intracerebral microinjections
Sponsor:   NeuroGeneration
Not yet recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT03309514

FIRST POSTED:
Fri, 13 Oct 2017 12:00:00 EDT

LAST UPDATE POSTED:
09/26/19 07:45AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03309514?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=09%2F12%2F2019&lupd_d=14&sort=nwst

Open-label Investigation of the Safety and Clinical Effects of NTCELL in Patients With Parkinson’s Disease

https://clinicaltrials.gov/ct2/show/NCT01734733?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=09%2F02%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
Open-label Investigation of the Safety and Clinical Effects of NTCELL in Patients With Parkinson’s Disease

DESCRIPTION:
Condition:   Parkinson’s Disease
Intervention:   Other: NTCELL
Sponsor:   Living Cell Technologies
Active, not recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT01734733

FIRST POSTED:
Wed, 28 Nov 2012 12:00:00 EST

LAST UPDATE POSTED:
09/16/19 07:45AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT01734733?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=09%2F02%2F2019&lupd_d=14&sort=nwst

Study of OXB-102 (AXO-Lenti-PD) in Patients With Bilateral, Idiopathic Parkinson’s Disease

https://clinicaltrials.gov/ct2/show/NCT03720418?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=08%2F16%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
Study of OXB-102 (AXO-Lenti-PD) in Patients With Bilateral, Idiopathic Parkinson’s Disease

DESCRIPTION:
Condition:   Parkinson Disease
Interventions:   Drug: OXB-102;   Other: Imitation Surgical Procedure (ISP)
Sponsors:   Axovant Sciences Ltd.;   Oxford BioMedica
Recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT03720418

FIRST POSTED:
Thu, 25 Oct 2018 12:00:00 EDT

LAST UPDATE POSTED:
08/30/19 09:00AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03720418?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=08%2F16%2F2019&lupd_d=14&sort=nwst

Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson’s Disease

https://clinicaltrials.gov/ct2/show/NCT03295786?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=06%2F21%2F2019&lupd_d=14&sort=nwst

Phase 1-2, Randomised, Double-Blind, Placebo Controlled, Safety and Tolerability Study of Intraputamenal Cerebral Dopamine Neurotrophic Factor (CDNF) Infusions Via an Investigational Drug Delivery System to Patients With Parkinson’s Disease

STUDY TITLE:
Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson’s Disease

DESCRIPTION:
Conditions:   Parkinson Disease;   Movement Disorders;   Neurodegenerative Diseases;   Nervous System Diseases;   Brain Diseases
Interventions:   Drug: Cerebral Dopamine Neurotrophic Factor;   Device: Renishaw Drug Delivery System
Sponsors:   Herantis Pharma Plc.;   Renishaw plc.
Recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT03295786

FIRST POSTED:
Thu, 28 Sep 2017 12:00:00 EDT

LAST UPDATE POSTED:
07/05/19 07:10AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03295786?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=06%2F21%2F2019&lupd_d=14&sort=nwst

Trial of Ursodeoxycholic Acid (UDCA) for Parkinson’s Disease: The “UP” Study

https://clinicaltrials.gov/ct2/show/NCT03840005?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F28%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
Trial of Ursodeoxycholic Acid (UDCA) for Parkinson’s Disease: The “UP” Study

DESCRIPTION:
Condition:   Parkinson’s Disease
Intervention:   Drug: Ursonorm
Sponsors:   Sheffield Teaching Hospitals NHS Foundation Trust;   JP Moulton Charitable Foundation;   PRO.MED.CS Praha a.s.;   Clinical Trials Research Unit, University of Sheffield
Recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT03840005

FIRST POSTED:
Fri, 15 Feb 2019 12:00:00 EST

LAST UPDATE POSTED:
06/11/19 06:55AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03840005?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F28%2F2019&lupd_d=14&sort=nwst

BTRX-246040 Study in Subjects With Parkinson’s Disease With Motor Fluctuations [Completed]

https://clinicaltrials.gov/ct2/show/NCT03608371?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F22%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
BTRX-246040 Study in Subjects With Parkinson’s Disease With Motor Fluctuations

DESCRIPTION:
Conditions:   Parkinson Disease;   Motor Disorder
Interventions:   Drug: BTRX-246040;   Drug: Placebo
Sponsor:   BlackThorn Therapeutics, Inc.
Completed

CLINICALTRIALS.GOV IDENTIFIER:
NCT03608371

FIRST POSTED:
Tue, 31 Jul 2018 12:00:00 EDT

LAST UPDATE POSTED:
06/05/19 07:44AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03608371?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F22%2F2019&lupd_d=14&sort=nwst

Clinical Trial to Evaluate the Safety and Tolerability of Molecular Hydrogen in Patients With Parkinson’s Disease

https://clinicaltrials.gov/ct2/show/NCT03971617?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F20%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
Clinical Trial to Evaluate the Safety and Tolerability of Hydrogen in Patients With Parkinson’s Disease

DESCRIPTION:
Condition:   Parkinson Disease
Interventions:   Drug: Hydrogen;   Drug: Placebo oral tablet
Sponsor:   Stony Brook University
Recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT03971617

FIRST POSTED:
Mon, 03 Jun 2019 12:00:00 EDT

LAST UPDATE POSTED:
06/03/19 07:42AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03971617?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F20%2F2019&lupd_d=14&sort=nwst

A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of GZ/SAR402671 in Parkinson’s Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation

https://clinicaltrials.gov/ct2/show/NCT02906020?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F08%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of GZ/SAR402671 in Parkinson’s Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation

DESCRIPTION:
Condition:   Parkinson’s Disease
Interventions:   Drug: GZ/SAR402671;   Drug: Placebo
Sponsor:   Genzyme, a Sanofi Company
Recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT02906020

FIRST POSTED:
Mon, 19 Sep 2016 12:00:00 EDT

LAST UPDATE POSTED:
05/22/19 07:42AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT02906020?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F08%2F2019&lupd_d=14&sort=nwst

A Study to Assess the Safety of GRF6021 Infusions in Subjects With Parkinson’s Disease and Cognitive Impairment

https://clinicaltrials.gov/ct2/show/NCT03713957?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F08%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
A Study to Assess the Safety of GRF6021 Infusions in Subjects With Parkinson’s Disease and Cognitive Impairment

DESCRIPTION:
Condition:   Parkinson Disease
Interventions:   Drug: GRF6021;   Other: Placebo
Sponsors:   Alkahest, Inc.;   Michael J. Fox Foundation for Parkinson’s Research
Recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT03713957

FIRST POSTED:
Mon, 22 Oct 2018 12:00:00 EDT

LAST UPDATE POSTED:
05/22/19 07:42AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03713957?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F08%2F2019&lupd_d=14&sort=nwst

Modulation of Gut Microbiota by Rifaximin in PD Patients

https://clinicaltrials.gov/ct2/show/NCT03958708?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F08%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
Modulation of Gut Microbiota by Rifaximin in PD Patients

DESCRIPTION:
Conditions:   Parkinson Disease;   Inflammation
Intervention:   Drug: Rifaximin 550 MG
Sponsor:   Taipei Medical University Shuang Ho Hospital
Recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT03958708

FIRST POSTED:
Wed, 22 May 2019 12:00:00 EDT

LAST UPDATE POSTED:
05/22/19 07:42AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03958708?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F08%2F2019&lupd_d=14&sort=nwst

Safety and Efficacy of THN102 in Patients With Parkinson’s Disease and Excessive Daytime Sleepiness

https://clinicaltrials.gov/ct2/show/NCT03624920?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F07%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
Safety and Efficacy of THN102 in Patients With Parkinson’s Disease and Excessive Daytime Sleepiness

DESCRIPTION:
Condition:   Parkinson Disease
Interventions:   Drug: THN102 Dosage A;   Drug: THN102 Dosage B;   Drug: THN102 Dosage C
Sponsor:   Theranexus
Recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT03624920

FIRST POSTED:
Fri, 10 Aug 2018 12:00:00 EDT

LAST UPDATE POSTED:
05/21/19 06:55AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03624920?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F07%2F2019&lupd_d=14&sort=nwst

VY-AADC02 for Parkinson’s Disease With Motor Fluctuations

https://clinicaltrials.gov/ct2/show/NCT03562494?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F06%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
VY-AADC02 for Parkinson’s Disease With Motor Fluctuations

DESCRIPTION:
Condition:   Parkinson Disease
Interventions:   Biological: VY-AADC02;   Other: Placebo
Sponsors:   Neurocrine Biosciences;   Voyager Therapeutics
Recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT03562494

FIRST POSTED:
Tue, 19 Jun 2018 12:00:00 EDT

LAST UPDATE POSTED:
05/20/19 07:34AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03562494?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F06%2F2019&lupd_d=14&sort=nwst

Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5HT2A Inverse Agonist, to Treat Impulse Control Disorders in Parkinson’s Disease

https://clinicaltrials.gov/ct2/show/NCT03947216?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=04%2F29%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5HT2A Inverse Agonist, to Treat Impulse Control Disorders in Parkinson’s Disease.

DESCRIPTION:
Condition:   Parkinson Disease
Interventions:   Drug: Active drug: pimavanserin 17mg (2 strength tablets);   Drug: Placebo: 2 tablets containing same excipients except active compound;   Behavioral: Assessment of severity of ICD (impulse control disorders);   Behavioral: Assessment of motor and non-motors symptoms of PD Evaluation of hyper- and hypodopaminergic behaviors;   Behavioral: Assessment of quality of life;   Behavioral: Assessment of depression;   Behavioral: Assessment of cognition;   Behavioral: Assessment of severity of Parkinson Disease;   Procedure: Blood analysis;   Procedure: Cardiac monitoring
Sponsor:   University Hospital, Strasbourg, France
Not yet recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT03947216

FIRST POSTED:
Mon, 13 May 2019 12:00:00 EDT

LAST UPDATE POSTED:
05/13/19 07:43AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03947216?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=04%2F29%2F2019&lupd_d=14&sort=nwst